Pharmacokinetics and Safety of Single‐Dose Inhaled Loxapine in Children and Adolescents. (16th May 2017)

• Record Type: Journal Article
• Authors: Selim, Sally; Riesenberg, Robert; Cassella, James; Kunta, Jeevan; Hellriegel, Edward; Smith, Mark A.; Vinks, Alexander A.; Rabinovich‐Guilatt, Laura
• Is Part Of: Journal of clinical pharmacology. Volume 57:Number 10(2017)
• Page Start: 1244
• Page End: 1257
• Publication Date: 2017-05-16
• Subjects: inhalation -- loxapine -- pediatric -- pharmacokinetics -- safety; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.932
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: This multisite open‐label study sought to characterize the pharmacokinetics and safety of a single dose of inhaled loxapine in children and adolescents. Loxapine powder for oral inhalation was administered via a single‐use handheld drug device to children and adolescents (aged 10–17 years) with any condition warranting chronic antipsychotic use. Patients were dosed according to body weight and cohort (<50 kg [n = 15], 2.5 or 5 mg; ≥50 kg [n = 15], 5 or 10 mg); the first 6 patients (cohort 1) enrolled in each weight group received the lower dose. Patients were enrolled in the higher‐dose group (cohort 2) after an interim pharmacokinetic and safety analysis of data from cohort 1. Blood samples were collected for 48 hours after dosing to determine the pharmacokinetic profile of loxapine and its metabolites. Safety was assessed using adverse event (AE), laboratory value, physical/neurologic examination, vital sign, electrocardiogram, suicidality, and extrapyramidal symptom assessment. Thirty patients were enrolled and evaluable for pharmacokinetics. Loxapine plasma concentrations peaked by 2 to 5 minutes in most patients; systemic exposure increased with dose in both weight subgroups. Loxapine terminal elimination half‐life was ∼13 to 17 hours. The most common AEs were sedation and dysgeusia. Sedation was severe in 1 patient in the <50‐kg group (2.5‐mg dose) and 1 patient in the ≥50‐kg group (5‐mg dose). No AEs indicative of bronchospasm or other serious AEs were reported. Inhaled loxapine was rapidly absorbed and generally well tolerated in pediatric patients; no new safety signals were observed.